The purpose of this study is to compare two different creams (5-fluorouracil, known as Efudix, and calcipotriol, known as Dovonex) to see which one works better when used before Photodynamic Therapy (PDT) to treat sun-damaged skin on the scalp (called actinic keratoses).
PDT is often used on its own to treat these spots, but it doesn't always remove them completely. Using Efudix or Dovonex before PDT might improve the results, but we don't yet know which is better.
The main questions are -
1. Is efudix or dovonex better at treating actinic keratoses when used prior to PDT
2. Is efudix or dovonex more tolerable for patients?
Participants will be randomised to treat their scalp with efudix or dovonex for seven days prior to their first PDT treatment. They will be reviewed on day 7, prior to starting PDT, and again a week later when they present for their second PDT treatment.
During follow up, patients will be reviewed at 28 days, 3, 6, 9, and 12 months after treatment.
At each of these visits, the number of actinic keratoses will be counted, graded, mapped and photographed to allow assessment of improvement before and after treatment.

Start Date01 Jan 2025

Sponsor / Collaborator

St. Vincent's University Hospital

NCT06499415 / RecruitingPhase 4IIT

Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis: a Multicentre Randomized Controlled Clinical Trial

5-Fluorouracil (5FU) is proven to be the most effective therapy in field directed treatment for AK, with Jansen et al. reporting a 1-year probability of treatment success of 74.7%. However, treatment with 5FU is associated with side effects, like erythema, itching, a burning sensation and crusting, and a burdensome dosing regimen of twice daily application for four weeks. This long treatment duration in combination with side-effects and overall lifestyle adjustments during treatment can be the reason for poor adherence and premature termination, and it can also lead to future refusal of 5FU therapy. Therefore, room for improvement lies in increasing the tolerability, in terms of side effects or treatment duration, while maintaining the efficacy of 5FU in the treatment of AK.
Addition therapy, which can shorten the duration of treatment, might be the key to success. Calcipotriol (CAL) enhances thymic stromal lymphopoietin (TSLP), an epithelium-derived cytokine, which promotes antitumor immunity. Therefore, it is known to have a synergistic effect when combined with 5FU in the treatment of AK. This suggests that short-term treatment with 5FU-CAL is effective and provides the opportunity to shorten duration of treatment, thereby improving tolerability of treatment and full adherence to the treatment regimen.
However, no study compared 5FU-CAL combination therapy with standard 5FU treatment for a duration of 28 days. This study aims to evaluate whether a short course of combination therapy with 5FU-CAL is non-inferior to a full course of 5FU monotherapy with respect to the 1-year probability of treatment success.

Start Date04 Sep 2024

Sponsor / Collaborator-

NCT05699603 / RecruitingPhase 2IIT

Phase IIA, Single-Arm, Open- Label, Clinical Trial of Calcipotriene Plus 5-fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients

This phase IIA study evaluates the effects of calcipotriene plus 5- fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients. Precancerous skin lesions, actinic keratoses (AK), may put organ transplant recipients at higher than average risk of developing skin cancer. Topical calcipotriene is a form of vitamin D and is used to treat psoriasis and topical 5- fluorouracil is a chemotherapy agent applied to the skin. The combination of calcipotriene plus 5- fluorouracil topical cream, which activates the immune cells against cancer, may help prevent skin cancer in organ transplant recipients who have precancerous skin lesions.

Start Date02 Jul 2024

Sponsor / Collaborator

University of Arizona

[+1]

100 Clinical Results associated with Calcipotriene

100 Translational Medicine associated with Calcipotriene

100 Patents (Medical) associated with Calcipotriene

1,565

Literatures (Medical) associated with Calcipotriene

31 Dec 2024·Journal of Dermatological Treatment

Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis

Review

Author: Wang, XinYue ; Shi, Lei ; Mu, ZengYi ; Wang, YaPing ; Li, XinHong ; Hu, Yue ; Li, ChanXiu ; Sun, Xiao

AIMThis study aimed to compare the efficacy and safety of excimer laser (EL)-based combination regimens in improving repigmentation.METHODSA comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, and Embase on July 1, 2023, to include randomized controlled trials of EL combination treatments for vitiligo that met the criteria. The primary outcome measure was a repigmentation rate ≥ 75%, and the secondary outcome measures were a repigmentation rate of ≤ 25% and adverse events.RESULTSEleven studies involving 348 patients were included. Network Meta-Analysis showed that EL combined with antioxidants (SUCRA = 98.8%), EL combined with calcipotriol (SUCRA = 59.8%) and EL combined with tacalcitol (SUCRA = 59.6%) were the three optimal interventions achieving repigmentation rates ≥ 75%. EL alone (SUCRA = 77.6%), EL combined with tacalcitol (SUCRA = 61.7%) and EL combined with antioxidants (SUCRA = 57.2%) were the three interventions with the highest rates of treatment failure. Adverse events in all groups mainly included erythema, burning sensation and hyperpigmentation. Based on the results of the current study, EL combination therapies were safe with mild adverse events.CONCLUSIONEL combined with antioxidants was the preferred regimen for vitiligo, whereas EL alone was the regimen with the highest rate of treatment failure in vitiligo.

31 Dec 2024·Journal of Dermatological Treatment

Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey

Article

Author: Galván, Jordi ; López Estebaranz, José Luis ; Kurzen, Hjalmar

BACKGROUNDPsoriasis significantly impacts patients' quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion (PAD) Technology containing a fixed-dose of calcipotriol (CAL) and betamethasone dipropionate (BDP) was designed for a patient-friendly psoriasis management. The CAL/BDP PAD-cream demonstrated efficacy, convenience, and safety/tolerability in clinical trials.OBJECTIVESThis research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.METHODSBetween September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.RESULTSThe survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.CONCLUSIONSPsoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.

01 Dec 2024·Current Computer-Aided Drug Design

Network Pharmacology, Molecular Docking and Experimental Verification Revealing the Mechanism of Fule Cream against Childhood Atopic Dermatitis

Article

Author: Qi, Yuenan ; Gao, Ying ; Liu, Chang ; Liu, Yuxin ; Guan, Jing ; Liu, Yi ; Ou, Ling ; Zhang, Jianmin ; Lv, Xiaoxi

Background:The Fule Cream (FLC) is an herbal formula widely used for the treatment of pediatric atopic dermatitis (AD), however, the main active components and functional mechanisms of FLC remain unclear. This study performed an initial exploration of the potential acting mechanisms of FLC in childhood AD treatment through analyses of an AD mouse model using network pharmacology, molecular docking technology, and RNA-seq analysis.Materials and Methods:The main bioactive ingredients and potential targets of FLC were collected from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and SwissTargetPrediction databases. An herb-compound-target network was built using Cytoscape 3.7.2. The disease targets of pediatric AD were searched in the DisGeNET, Therapeutic Target Database (TTD), OMIM, DrugBank and GeneCards databases. The overlapping targets between the active compounds and the disease were imported into the STRING database for the construction of the protein-protein interaction (PPI) network. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the intersection targets were performed, and molecular docking verification of the core compounds and targets was then performed using AutoDock Vina 1.1.2. The AD mouse model for experimental verification was induced by MC903.Results:The herb-compound-target network included 415 nodes and 1990 edges. Quercetin, luteolin, beta-sitosterol, wogonin, ursolic acid, apigenin, stigmasterol, kaempferol, sitogluside and myricetin were key nodes. The targets with higher degree values were IL-4, IL-10, IL-1α, IL-1β, TNFα, CXCL8, CCL2, CXCL10, CSF2, and IL-6. GO enrichment and KEGG analyses illustrated that important biological functions involved response to extracellular stimulus, regulation of cell adhesion and migration, inflammatory response, cellular response to cytokine stimulus, and cytokine receptor binding. The signaling pathways in the FLC treatment of pediatric AD mainly involve the PI3K-Akt signaling pathway, cytokine‒cytokine receptor interaction, chemokine signaling pathway, TNF signaling pathway, and NF-κB signaling pathway. The binding energy scores of the compounds and targets indicate a good binding activity. Luteolin, quercetin, and kaempferol showed a strong binding activity with TNFα and IL-4.Conclusion:This study illustrates the main bioactive components and potential mechanisms of FLC in the treatment of childhood AD, and provides a basis and reference for subsequent exploration.

News (Medical) associated with Calcipotriene

15 Nov 2024

·www.prnewswire.com

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene and betamethasone dipropionate) in Canada through Endo's subsidiary Paladin Pharma Inc. "We look forward to working with MC2 to make Wynzora® Cream available to Canadians who suffer from plaque psoriasis," said Livio Di Francesco, Vice President and General Manager of Paladin. "If approved by Health Canada, Wynzora® Cream's unique formulation and clinical profile will offer patients a new treatment option designed for convenience of use in daily routines." "Paladin has an experienced and dedicated team, and we're pleased to work with them to introduce Wynzora® Cream in Canada," said Jesper J. Lange, Chief Executive Officer, MC2 Therapeutics. "The agreement aligns with our strategy to make Wynzora® Cream available to as many patients suffering from plaque psoriasis as possible globally." Wynzora® Cream was approved in the US by the FDA on July 20, 2020 and launched in Europe on February 18, 2022. About Wynzora® Cream Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2's formulation and drug delivery system PAD Technology™, allowing a convenient-to-use aqueous formulation. About Endo and Paladin Pharma Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at or connect with us on LinkedIn. Paladin Pharma Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing, medical and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo, Inc. For more information, visit . About MC2 Therapeutics () MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation. Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking. Besides Wynzora® Cream, MC2 has a pipeline that includes two first-in-class drug candidates, both in Phase 2 clinical development. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Messrs. Di Francesco and Lange and any statements relating to product development and commercialization, treatment options and therapies, regulatory approval, efficacy and product availability. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, unfavorable or delayed regulatory review, uncertainties in and the timing for regulatory approval, changes in competitive, market or regulatory conditions, and consumer and physician acceptance of current and new products. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A. SOURCE Endo, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalLicense out/inPhase 2

30 Sep 2024

·www.pharmaceutical-technology.com

LEO Pharma announces Enstilar NDA submission for plaque psoriasis in China

The review process is set for completion in H1 2026. Credit: Hriana via Shutterstock. Leo Pharma has submitted a New Drug Application (NDA) to China’s National Medical Products Administration for Enstilar, targeting the treatment of adult patients with plaque psoriasis. Enstilar is an aerosol spray foam combining calcipotriol and betamethasone, designed to improve upon the existing Daivobet ointment, which is currently a standard treatment in China. The submission follows a series of milestones for LEO Pharma in the EU and the US, with China potentially becoming the largest market for Enstilar. The NDA is supported by a Phase III trial involving 604 adult Chinese subjects with stable plaque psoriasis. This trial showed Enstilar to be superior to Daivobet ointment, achieving both primary and secondary endpoints. See Also: FDA approves PureTech’s KarXT to treat schizophrenia in adults FDA greenlights Regeneron’s Dupixent for the treatment of COPD The Center for Drug Evaluation (CDE) in China will now validate and fully evaluate the NDA. The regulatory review process is anticipated to be completed in the first half (H1) of 2026. LEO Pharma China general manager Byron Yin said: “LEO Pharma strives to enhance patient care and elevate quality of life for those living with complex skin conditions like plaque psoriasis. “Today’s submission is a crucial step towards offering a much-needed new treatment option in our region, in addition to the existing portfolio offering from LEO Pharma China.” Enstilar is already indicated in the EU for up to four weeks of treatment for psoriasis vulgaris in adults, with suitable candidates eligible for long-term maintenance. Recently, the European Commission authorised Leo Pharma’s Anzupgo cream for treating adults with moderate to severe chronic hand eczema .

Phase 3NDAClinical ResultDrug Approval

27 Sep 2024

·www.businesswire.com

LEO Pharma Submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China

BALLERUP, Denmark--( BUSINESS WIRE )-- NOT INTENDED FOR DISTRIBUTION IN THE UK LEO Pharma A/S, a global leader in medical dermatology, has today announced its submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for Enstilar ® (LEO 90100) to treat adult patients living with plaque psoriasis. Following a week of significant LEO Pharma treatment and data milestones in the EU and the U.S., today’s news of the NDA submission in China is the latest example of LEO Pharma’s global strategy in action across medical dermatology. If approved, China would join 50 other markets in the world to be approved to bring Enstilar to patients, and would be the largest country to date. Enstilar ® , a calcipotriol/betamethasone cutaneous foam, is an improved formulation of Daivobet ® ointment, which is one of the current standard treatment options in China for adults living with plaque psoriasis. 4 Both Daivobet ointment and Enstilar are LEO Pharma products. “ LEO Pharma strives to enhance patient care and elevate quality of life for those living with complex skin conditions like plaque psoriasis ,” said Byron Yin, General Manager for LEO Pharma, China. “ Today’s submission is a crucial step towards offering a much-needed new treatment option in our region, in addition to the existing portfolio offering from LEO Pharma China.” “ Today’s submission of our NDA for Enstilar is a testament to LEO Pharma’s truly global outlook and ambition in advancing dermatology, following on from a week of milestones across both the EU and U.S.” said Becki Morison, Executive Vice President, Global Product Strategy & International Operations for LEO Pharma. “ China is a key market for LEO Pharma, with dermatology growing rapidly in the country and our revenue steadily increasing through a strong performance from our team. We will continue to leverage our extensive dermatology expertise to enhance the treatments we can provide in the region, unwavering in our goal to provide support to those in China that need it most.” The NDA submission is supported by results from a phase 3 trial comparing the efficacy and safety of a once daily application with Enstilar and Daivobet ointment after 4 weeks of treatment in adult Chinese subjects with stable plaque psoriasis (N=604). 1,2 The trial achieved its primary and secondary endpoints, with Enstilar demonstrating superiority to Daivobet ointment. 2 “ The trial showed the potential that Enstilar has to improve the quality of life for millions of Chinese patients living with plaque psoriasis,” said Professor Zhang Jianzhong from Peking University People's Hospital, lead investigator of the phase 3 Enstilar trial. “ Through today’s milestone, we take a step towards new treatment options for the millions that live with plaque psoriasis in the near future.” Following the Enstilar submission, the Centre for Drug Evaluation (CDE) will validate the filing, before the full evaluation of the NDA is conducted by the CDE. The regulatory review process is expected to conclude in the first half of 2026. About Enstilar ® Enstilar ® is an aerosol spray foam containing calcipotriol monohydrate 50 mcg/g and betamethasone dipropionate 0.5 mg/g. In the EU, it is indicated for the treatment of psoriasis vulgaris in adults for up to 4 weeks. Patients who have responded at 4 weeks’ treatment using Enstilar once daily are suitable for long-term maintenance treatment. 4-7 About Psoriasis Psoriasis is a chronic, systemic inflammatory disease that primarily affects the skin in 125 million people worldwide. 8,9 Psoriasis is the result of skin barrier cell proliferation and the activation of cytokines (a family of proteins involved in immune responses) that cause inflammation. 10 About 80% to 90% of patients are affected by plaque psoriasis, the most common clinical form of psoriasis. 11 The symptoms of plaque psoriasis are itchy or painful raised scaly and inflamed plaques. Plaques may appear anywhere on the body, but often appear on the scalp, knees, elbows and torso. 11 About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion. References ClinicalTrials.gov. National Library of Medicine (U.S.). A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis. Identifier: NCT05919082. https://clinicaltrials.gov/study/NCT05919082 . LEO Pharma Press Release. LEO Pharma Announces Topline Results of Phase 3 Trial in China for Enstilar® (LEO 90100) Demonstrating Superiority in Adult Chinese Subjects With Stable Plaque Psoriasis. Published: May 04, 2024. Last accessed: Sep 25, 2024. Available at: https://www.businesswire.com/news/home/20240507292614/en/LEO-Pharma-Announces-Topline-Results-of-Phase-3-Trial-in-China-for-Enstilar%C2%AE-LEO-90100-Demonstrating-Superiority-in-Adult-Chinese-Subjects-With-Stable-Plaque-Psoriasis . Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663-667. Zhang, XJ et al., Chin J Dermatol, July 2023, Vol. 56, No. 7, Guideline for the diagnosis and treatment of psoriasis in China (2023 edition) Enstilar ® EU Summary of Product Characteristics July 2022. Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127. Leonardi C, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris—a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659. National Psoriasis Foundation. Psoriasis Statistics. Last updated: Dec 21, 2022. Last accessed: Sep 25, 2024. Available at: https://www.psoriasis.org/content/statistics . Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653. National Psoriasis Foundation. Plaque Psoriasis. Last updated: Feb 08, 2024. Last accessed: Sep 25, 2024. Available at: https://www.psoriasis.org/plaque/ . MAT-76612 September 2024

Phase 3Clinical ResultPhase 2NDAImmunotherapy

100 Deals associated with Calcipotriene

External Link

KEGG	Wiki	ATC	Drug Bank
D01125	Calcipotriene	D05AX02	DB02300

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Psoriasis vulgaris	JP	Leo Pharma, Inc.	18 Jan 2000
Plaque psoriasis	US	LEO Pharma A/S	29 Dec 1993
Psoriasis	-	Leo Pharma, Inc.	01 Jan 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis	Phase 3	IN	Lipidor AB	03 Oct 2018
Plaque psoriasis	Phase 3	IN	Cadila Pharmaceuticals Ltd.	20 Aug 2018
Psoriasis vulgaris	Phase 3	GB	Leo Pharma, Inc.	01 Feb 2008
Psoriasis vulgaris	Phase 3	FR	Leo Pharma, Inc.	01 Feb 2008
Psoriasis vulgaris	Phase 3	CA	Leo Pharma, Inc.	01 Feb 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCD2023	Not Applicable	Pityriasis Rubra Pilaris First line	-	Methotrexate	(xfdwtlshja) = pbtgdzrjqm tmktrrfhyu (acdsizflcy ) View more	-	03 Jul 2023
				Topical Calcipotriol	(xfdwtlshja) = wztwmwwloz tmktrrfhyu (acdsizflcy ) View more
phase 3 (EADV2022)	Phase 3	Plaque psoriasis	796	Calcipotriene and betamethasone dipropionate cream	fizkdpxuog(sctuzoxwbf) = lhiocphzpp wwimksmqap (hbemyzbjbq ) View more	Positive	07 Sep 2022
				Calcipotriene and betamethasone dipropionate gel	fizkdpxuog(sctuzoxwbf) = hcpmbvsptv wwimksmqap (hbemyzbjbq ) View more
Pubmed Manual	Not Applicable	Psoriasis vulgaris	166	Calcipotriene+LEO90100	(fmlsncxome) = ltcuqpbhys ypafdazkcw (nlhkwnnxcw, 3.0) View more	Positive	18 Jul 2022
EADV2022	Not Applicable	Plaque psoriasis	-	Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g aerosol foam	zczjlnabgf(cadxrsibhu) = laqalerqle vdsontqjqu (rutrtsykwh )	-	12 May 2022
				Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cream	zczjlnabgf(cadxrsibhu) = wdrfsthvtb vdsontqjqu (rutrtsykwh )
EADV2022	Not Applicable	Plaque psoriasis	-	Calcipotriol 0.005% plus betamethasone dipropionate 0.064% foam	uxhmfdytgu(hrfnosqdbp) = 0.8%/0.1% vs 7.4% wcqgnzypmi (ijbvvhndvq ) View more	-	12 May 2022
				Halobetasol propionate 0.01% plus tazarotene 0.045% lotion
NCT01445886 (CTgov)	Phase 2/3	Psoriasis of nail	33	Calcipotriol Solution	tdzosstqig(pgqyxhpusq) = baxqhqmaoj tmxgdxlwdw (xhpyijnzvu, ugnjmevxxg - nwixgrbkjg) View more	-	28 Aug 2019
NCT01694433 (CTgov)	Phase 2/3	Acne Vulgaris	66	Calcipotriene (Calcipotriene Cream)	queihaabbx(wuynlfuvzx) = xqttxqweoh wpznaqgtua (htdyrafcdp, sffilecfoa - furvdahcub) View more	-	07 May 2019
				Placebo (Placebo)	queihaabbx(wuynlfuvzx) = irzubeagtl wpznaqgtua (htdyrafcdp, kkxefztzkd - ntexglbezx) View more
NCT00764751 (CTgov)	Phase 2	Psoriasis vulgaris	51	LEO 80122+calcipotriol+LEO 19123 (Group A: LEO 19123)	wkehmgwtsh(pcpvokkzja) = xzmqdzitcg pyljiqzfmv (mzhdhpzrgw, pmcesumabs - bsuqxxsytd) View more	-	06 May 2019
				Dovonex (Group A: Dovonex®)	wkehmgwtsh(pcpvokkzja) = kzgprbgjtz pyljiqzfmv (mzhdhpzrgw, bcjkuikksl - xyyqrihddq) View more
NCT01745133 (CTgov)	Phase 4	Plaque psoriasis	63	Vehicle Foam	xxgqoqxhrh(lapjiwnrwq) = pfquircomx esejxsofik (ilsqtnugmh, tqdieyqgqh - tpnsnlflxm) View more	-	17 Nov 2016
NCT02193815 (CTgov)	Phase 1	Plaque psoriasis \| Psoriasis vulgaris	15	PF-06263276 (PF-06263276 4% Solution)	recnzvgzlu(broodrxgia) = cxerhuhokn pizqbeueyy (dmqplsjokb, jcgjerbzgt - ioyjgykqyi) View more	-	09 Jun 2016
				PF-06263276 (PF-06263276 Vehicle)	recnzvgzlu(broodrxgia) = precsnnssk pizqbeueyy (dmqplsjokb, fpmzssswib - zladrkszcw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis